NCT07619248

Brief Summary

Colorectal cancer (CRC) is one of the most common cancers worldwide. These malignancies originate in the colon or rectum, and the majority evolve from pre-existing colonic adenomas (a type of colon polyp). Early detection, identification, and removal of these precancerous lesions can effectively reduce the morbidity and mortality of colorectal cancer. However, not all colonic polyps possess a significant risk of malignant transformation. Polyps can generally be subdivided into "neoplastic" and "non-neoplastic" lesions; major non-neoplastic polyps include inflammatory polyps, hamartomas, lymphoid polyps, mucosal prolapse polyps, and hyperplastic polyps. On the other hand, neoplastic polyps have the potential to develop into malignancies, primarily including adenomatous polyps and serrated polyps. Adenomatous polyps account for more than 50% of all colonic polyps and are the most common precancerous lesions for CRC. Clinically, they can be further classified into tubular, tubulovillous, or villous adenomas based on histological subtypes. As for serrated polyps, traditional serrated adenomas (TSAs) and sessile serrated lesions (SSLs) possess carcinogenic potential. During a colonoscopy, detecting colonic polyps is crucial, but it is equally important to identify which polyps have malignant potential. This allows for the accurate resection of true precancerous lesions while avoiding the procedural risks associated with unnecessary polypectomies. Furthermore, in rare instances, diminutive polyps may harbor cancer with deep submucosal invasion. Due to the risks of incomplete resection and lymph node metastasis, such lesions are not suitable for endoscopic resection. Therefore, achieving an accurate endoscopic diagnosis is a key step in determining the most appropriate management strategy for colonic polyps. To improve the diagnostic accuracy of endoscopy for colonic polyps, multiple modalities have been developed, including careful observation of lesion morphology, as well as various image-enhanced technologies and chromoendoscopy. Meanwhile, three-dimensional (3D) endoscopy, a novel technology, offers superior spatial resolution and depth perception compared to conventional two-dimensional (2D) endoscopy. Studies have confirmed that 3D endoscopy can improve the adenoma detection rate (ADR) due to its enhanced ability to detect flat and inconspicuous lesions. However, whether 3D colonoscopy can also enhance the endoscopic diagnostic accuracy for colonic polyps remains to be explored. Therefore, we designed a randomized controlled trial (RCT) to investigate whether 3D colonoscopy can improve the diagnostic accuracy of colonic polyps compared to conventional 2D colonoscopy.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
600

participants targeted

Target at P75+ for not_applicable

Timeline
9mo left

Started May 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
May 2026May 2027

Study Start

First participant enrolled

May 12, 2026

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

May 19, 2026

Completed
13 days until next milestone

First Posted

Study publicly available on registry

June 1, 2026

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 12, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 12, 2027

Last Updated

June 1, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

May 19, 2026

Last Update Submit

May 28, 2026

Conditions

Keywords

EndoscopyColonoscopyColo-rectal polyps3D Endoscopy

Outcome Measures

Primary Outcomes (1)

  • diagnosis accuracy rate (DAR) of polyps under different endoscopic modes

    Primary Endpoints: The primary endpoint of this study is to compare the diagnosis accuracy rate (DAR) of polyps under different endoscopic modes to determine if there is a significant difference between 3D and 2D colonoscopy. This is primarily calculated by comparing the pathological diagnosis of the resected polyps sent for laboratory testing with the 3D and 2D endoscopic diagnoses, which represents the diagnostic consistency rate. In practical application, each polyp will receive a 3D diagnosis and a 2D diagnosis (regardless of the order), as well as a pathological diagnosis. If the 3D diagnosis of a polyp aligns with the pathological diagnosis, it is considered a correct diagnosis; otherwise, it is deemed incorrect. The DAR is the proportion of correct diagnoses out of the total number of polyps analyzed.

    12 months

Study Arms (2)

2D-3D sequence

EXPERIMENTAL

When subjects undergo the colonoscopy, the operator will use the conventional 2D endoscopic mode for insertion. Once the colonoscope reaches the cecum, a research assistant will randomly assign the subject to one of the two endoscopic modality sequences using a sealed envelope, with an expected 1:1 allocation ratio between the two groups. The primary difference between the two groups occurs during the withdrawal of the endoscope from the cecum to the anus. If a polyp lesion is detected, one group will first use conventional 2D imaging for polyp diagnosis, and then switch to 3D endoscopy for a second diagnosis. The other group will do the reverse: completing the diagnosis with 3D endoscopy first, and then switching to conventional 2D endoscopy for a second diagnosis. This design aims to eliminate judgment bias caused by the diagnostic sequence.

Device: 3D MonoStereo

3D-2D sequence

OTHER

When subjects undergo the colonoscopy, the operator will use the conventional 2D endoscopic mode for insertion. Once the colonoscope reaches the cecum, a research assistant will randomly assign the subject to one of the two endoscopic modality sequences using a sealed envelope, with an expected 1:1 allocation ratio between the two groups. The primary difference between the two groups occurs during the withdrawal of the endoscope from the cecum to the anus. If a polyp lesion is detected, one group will first use conventional 2D imaging for polyp diagnosis, and then switch to 3D endoscopy for a second diagnosis. The other group will do the reverse: completing the diagnosis with 3D endoscopy first, and then switching to conventional 2D endoscopy for a second diagnosis. This design aims to eliminate judgment bias caused by the diagnostic sequence.

Device: 3D MonoStereo

Interventions

When subjects undergo the colonoscopy, the operator will use the conventional 2D endoscopic mode for insertion. Once the colonoscope reaches the cecum, a research assistant will randomly assign the subject to one of the two endoscopic modality sequences using a sealed envelope, with an expected 1:1 allocation ratio between the two groups. The primary difference between the two groups occurs during the withdrawal of the endoscope from the cecum to the anus. If a polyp lesion is detected, one group will first use conventional 2D imaging for polyp diagnosis, and then switch to 3D endoscopy for a second diagnosis. The other group will do the reverse: completing the diagnosis with 3D endoscopy first, and then switching to conventional 2D endoscopy for a second diagnosis. This design aims to eliminate judgment bias caused by the diagnostic sequence.

2D-3D sequence3D-2D sequence

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 18 years or older.
  • Patients who meet the indications for undergoing colonoscopy.

You may not qualify if:

  • Patients younger than 18 years of age or those with contraindications precluding them from undergoing a colonoscopy.
  • (Contraindications for colonoscopy: patients with a recent history of myocardial infarction, pulmonary embolism, cerebrovascular infarction, severe unstable cardiovascular disease, acute abdominal inflammation combined with peritonitis, fulminant colitis, acute diverticulitis, colonic perforation, or toxic megacolon).
  • Patients with familial hereditary colorectal cancer or colonic polyposis syndromes.
  • Patients with inflammatory bowel disease (IBD).
  • Subjects who are unable to complete the colonoscopy or those with poor bowel preparation.
  • Subjects who are unable to confirm the date of their previous colonoscopy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Li-Chun Chang, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 19, 2026

First Posted

June 1, 2026

Study Start

May 12, 2026

Primary Completion (Estimated)

May 12, 2027

Study Completion (Estimated)

May 12, 2027

Last Updated

June 1, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share